Gilead Sciences has significantly expanded its footprint in the immunology and inflammatory bowel disease (IBD) therapeutic landscapes through a multi-billion-dollar…
Read More
Roche Acquires Global Rights to Alector’s Parkinson’s Disease Candidate AL050 in Landmark $1.27bn Deal
Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m Deal
Tolerance Bio has finalized a high-stakes licensing agreement with Tanabe Pharma, acquiring exclusive worldwide commercialization rights—excluding Japan—for TLB-33, a clinical-stage…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
Decoding Legal Trends and Emerging Considerations in Laboratory Data with a Focus on Value, Clarifying Ownership and Access Rights, Protecting Data, and Strategically Monetizing Information
Cleveland, OH – In a significant event for the legal and business communities, Elizabeth Sullivan, JD, and Emily Johnson, JD,…
Read More
GSK Secures Promising Metabolic Oligonucleotide Therapy Rights from SiranBio in Up to $1 Billion Deal
In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
